The NeuMoDx™ 96 and 288 Molecular Systems were formally launched at the QIAGEN booth at ESCV 2018 in Athens, Greece, provided robust feedback from clinicians, researchers, lab workers and industry members.
Listen to what people are saying about our systems by watching the video below.
We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.
To learn more, click here.
